Answers are grounded in this paper and cite their sources.
Immune cell infiltration predicts clinical outcome in DDLPS, with CD4+ cells associated with better outcomes; CD14+ cells and M2 macrophages are associated with worse outcomes. Future checkpoint inhibitor studies in DDLPS should incorporate immunosequencing and gene expression profiling techniques that can generate immune landscape profiles.
No takes yet. Share an insight, caveat, or question.
Schroeder et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: